An experienced analytical project manager, Peter brings almost 20 years combined Drug Metabolism and Pharmacokinetic (DMPK) experience gained through working for CROs, as a consultant and with large Pharma companies in both the Discovery and Development arenas.
With a speciality in mass spectrometry and bioanalysis, Peter has used his expertise in both large and small molecule analysis to deliver pre-clinical and clinical bioanalytical support to numerous drug projects.
Commenting on the appointment, Managing Director, Richard Weaver said, “I am delighted to welcome Peter to the team. Peter will be vital in helping XenoGesis to further enhance the analytical capabilities and experience within the business. He brings with him an extensive and varied background of method development skills in both large and small molecules that will increase the range of options available to us when offering expert DMPK services to our clients.”
He continues, “We are planning to invest in another specialist mass spectrometer this year and Peter, alongside our Biotransformation expert Iain Beattie, will be key in helping us maximising the impact of this state of the art equipment.
“This continues to be an exciting time for us in terms of growth. We are experiencing an increasing number of clients that are choosing to work with us because of our consultative approach to all our client projects, ensuring the most effective outcomes.”
Commenting on his appointment, Peter said, “I am looking forward to playing my part in helping to grow this exciting and dynamic business.”
XenoGesis is a specialist CRO focusing in preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis and expert interpretation. Founded by Richard Weaver in 2011 the business now employs 18 members of staff working at its premises in BioCity Nottingham.
For more information, visit the XenoGesis website.
